drugset / Trial / NCT04913389
Acetazolamide to Prevent Impending Altitude-illness in Patients With COPD
Phase 3
Unknown
100 enrolled
University of Zurich
National Center of Cardiology and Internal Medicine, Kyrgyz Republic · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this randomized, placebo-controlled double-blind trial is to evaluate efficacy of acetazolamide in preventing overt altitude-related adverse health effects (ARAHE) in lowlanders with chronic obstructive pulmonary disease (COPD) developing early signs of altitude-illness during altitude travel.
Timeline
- Start
- 2021-06-01
- Primary completion
- 2022-08-10
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Acetazolamide | Small molecule | 125 mg | Oral |
| Comparator | Acetazolamide | Small molecule | 250 mg | Oral |